Thomas W. P. Friedl

University Hospital Ulm — Germany

Medicine · Health Sciences

33h-index4.2kcitations312works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(89), Cancer Genomics and Diagnostics(75), Breast Cancer Treatment Studies(74), Advanced Breast Cancer Therapies(61), Cancer Treatment and Pharmacology(53)

Publications312 total

Age-dependent differences in survival of patients with early breast cancer: analysis of SUCCESS A, B, C trials
Archives of Gynecology and Obstetrics·2026Open Access
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy
PLoS ONE·2025Open Access
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
PLoS ONE·2025Open Access
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
International Journal of Molecular Sciences·2025· 1 citedOpen Access
424TiP The SURVIVE study: Evaluating liquid biopsy-guided follow-up in early breast cancer
Annals of Oncology·2025
Abstract P2-07-28: Treatment de-escalation by omission of chemotherapy & the effect of adding the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer– second interim efficacy analysis of the randomized DETECT V trial
Clinical Cancer Research·2025
Das vergessene Geschlecht – Wie erleben Väter einen ungeplanten Kaiserschnitt ihrer Partnerin? Eine explorative Studie
PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie·2025
Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Figure S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Table S5 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Table S9 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
Supplementary Table S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025Open Access
page 1 of 16Next →

Frequent Co-authors

Wolfgang Janni(29), Brigitte Rack(21), Tanja Fehm(16), Peter A. Fasching(15), Andreas Schneeweiß(14), Amelie de Gregorio(11), Nikolaus de Gregorio(11), Jens Huober(10), Klaus Pantel(9), Elisabeth Trapp(8), Ulrich Andergassen(7), Matthias W. Beckmann(7), Nadia Harbeck(7), Christoph Scholz(7), Peter Widschwendter(7), Andreas D. Hartkopf(7), Krisztián Látó(6), Marianna Alunni‐Fabbroni(6), Inga Bekes(6), F Meier-Stiegen(6)